Recently, Starna Therapeutics has proudly announced the successful closure of its Series B+ funding round, amassing nearly US$40 million. This investment was jointly made by esteemed industry funds and Hillhouse Ventures, alongside other prominent institutions. Earlier, within a mere six-month span, the company had already secured US$44 million in Series B financing, attracting backing from renowned investors.

The freshly acquired capital will be strategically allocated to expedite the clinical development of multiple in vivo cell therapy pipelines. Additionally, it will fuel the advancement of an extrahepatic delivery platform and reinforce Starna Therapeutics' pioneering R&D framework in the realm of mRNA therapeutics. As a clinical-stage enterprise, Starna Therapeutics is dedicated to mRNA drug development, boasting a diverse and robust R&D pipeline that spans several therapeutic areas.